Kintara Therapeutics Granted Fast Track Designation from FDA for REM-001 for Cutaneous Metastatic Breast Cancer November 28, 2022 • 8:00 AM EST
Kintara Therapeutics Presents Three Posters at the 2022 Society for Neuro-Oncology Annual Meeting November 18, 2022 • 8:00 AM EST
Kintara Therapeutics Announces Fiscal 2023 First Quarter Financial Results and Provides Corporate Update November 9, 2022 • 5:20 PM EST
Kintara Therapeutics Pauses REM-001 Program to Conserve Funds to Support VAL-083 International Registrational Study October 19, 2022 • 8:15 AM EDT
Kintara Therapeutics Announces Fiscal 2022 Financial Results and Provides Corporate Update September 27, 2022 • 8:15 AM EDT
Kintara Therapeutics Announces Three Abstracts Have Been Accepted for the 2022 Society for Neuro-Oncology Annual Meeting September 8, 2022 • 7:00 AM EDT
Kintara Therapeutics Receives Study May Proceed Letter from the FDA for REM-001 for Cutaneous Metastatic Breast Cancer August 9, 2022 • 9:00 AM EDT
Kintara Therapeutics Enters Into Equity Purchase Agreement for Up to $20 Million with Lincoln Park Capital August 3, 2022 • 8:30 AM EDT
Kintara Therapeutics to Present at the Alliance Global Partners Summer Healthcare Conference June 21, 2022 • 8:00 AM EDT